Rigel Pharmaceuticals (RIGL) Change in Account Payables (2016 - 2025)
Rigel Pharmaceuticals has reported Change in Account Payables over the past 16 years, most recently at $3.3 million for Q4 2025.
- For Q4 2025, Change in Account Payables rose 802.73% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.9 million, up 201.29%, while the annual FY2025 figure was $3.9 million, 201.29% up from the prior year.
- Change in Account Payables for Q4 2025 was $3.3 million at Rigel Pharmaceuticals, up from -$3.4 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $4.8 million in Q4 2022 and troughed at -$3.4 million in Q3 2025.
- A 5-year average of $175600.0 and a median of $600500.0 in 2022 define the central range for Change in Account Payables.
- Biggest five-year swings in Change in Account Payables: crashed 383.68% in 2021 and later soared 802.73% in 2025.
- Year by year, Change in Account Payables stood at $697000.0 in 2021, then soared by 586.8% to $4.8 million in 2022, then crashed by 117.9% to -$857000.0 in 2023, then surged by 44.46% to -$476000.0 in 2024, then soared by 802.73% to $3.3 million in 2025.
- Business Quant data shows Change in Account Payables for RIGL at $3.3 million in Q4 2025, -$3.4 million in Q3 2025, and $3.3 million in Q2 2025.